US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
MSTR
$160.01
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
MSTR
$160.01
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Helus Pharma Inc. - Common Stock
(NQ:
HELP
)
11.70
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Helus Pharma Inc. - Common Stock
< Previous
1
2
3
Next >
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
July 21, 2026
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data...
Via
FinancialNewsMedia
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
July 21, 2026
From
Helus Pharma
Via
GlobeNewswire
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity
From
MarketNewsUpdates.com
Via
GlobeNewswire
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal 2026 Results, Highlights Phase 3 Progress
June 29, 2026
Via
Investor Brand Network
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
June 29, 2026
From
Helus Pharma
Via
GlobeNewswire
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Closes $50 Million Public Offering
June 25, 2026
Via
Investor Brand Network
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
June 25, 2026
From
Helus Pharma
Via
GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Prices $50 Million Public Offering
June 24, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Surpasses 86% Enrollment in Phase 3 APPROACH Trial
June 24, 2026
Via
Investor Brand Network
FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
June 24, 2026
EQNX::TICKER_START (NASDAQ:HELP) EQNX::TICKER_END
Via
FinancialNewsMedia
Helus Pharma™ Announces US$50 Million Underwritten Offering
June 24, 2026
From
Helus Pharma
Via
GlobeNewswire
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
June 24, 2026
From
Helus Pharma
Via
GlobeNewswire
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Chief Medical Officer to Participate in H.C. Wainwright Neuro Perspectives Conference
June 11, 2026
Via
Investor Brand Network
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
June 11, 2026
From
Helus Pharma
Via
GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Jefferies Global Healthcare Conference
June 01, 2026
Via
Investor Brand Network
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
June 01, 2026
From
Helus Pharma
Via
GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Issues Correction To TARA Mind Partnership Announcement
May 01, 2026
Via
Investor Brand Network
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
April 30, 2026
From
Helus Pharma
Via
GlobeNewswire
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
April 30, 2026
From
Helus Pharma
Via
GlobeNewswire
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Partners With TARA Mind to Support Phase 3 Trial Recruitment in Veterans
April 28, 2026
Via
Investor Brand Network
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
April 28, 2026
From
Helus Pharma
Via
GlobeNewswire
BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Adds Robert Langer, Stephen Brannan To Scientific Advisory Board
April 23, 2026
Via
Investor Brand Network
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
April 23, 2026
From
Helus Pharma
Via
GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Supports Executive Order Advancing Psychedelic Therapies
April 20, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO Steps Down, Eric So Named Interim Chief Executive Office
April 20, 2026
Via
Investor Brand Network
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
April 20, 2026
From
Helus Pharma
Via
GlobeNewswire
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
April 20, 2026
From
Helus Pharma
Via
GlobeNewswire
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Ken Kramer SVP Medical Affairs
April 16, 2026
Via
Investor Brand Network
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
April 16, 2026
From
Helus Pharma
Via
GlobeNewswire
< Previous
1
2
3
Next >
